US FDA Proposes More Stringent UDI Requirements For Some Device 'Convenience Kits'
This article was originally published in SRA
The US Food and Drug Administration is inviting stakeholder feedback on its proposal to impose more stringent unique device identification (UDI) labeling requirements to make it easier to track individual components of "convenience kits" if they are reused or used in different procedures1,2.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.